熱門資訊> 正文
Edgewise在古根海姆收购了两条管道前景
2025-05-01 01:44
- Guggenheim has initiated Edgewise Therapeutics (NASDAQ:EWTX) at buy citing two pipeline candidates in mid-to-late stage development that could be potential blockbusters.
- The investment bank has a $41 price target (~165% upside based on April 29 close).
- Analyst Debjit Chattopadhyay said that the two assets, EDG-7500 and sevasemten for, respectively, hypertrophic cardiomyopathy and muscular dystrophies, could drive risk-adjusted sales of $2.4B by 2034.
- He noted that EDG-7500 could become a front-line option for a significant percentage of patients, as well as an alternative for patients who don't respond well to the HCM standard of care.
- Chattopadhyay added that HCM is slated to become a $7B+ total addressable market by 2035.
- He wrote that sevasemten, an oral, first-in-class fast myosin inhibitor, could be the first treatment approved for Becker muscular dystrophy. It is also under investigation for Duchenne muscular dystrophy.
More on Edgewise Therapeutics
- Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On
- Edgewise Therapeutics: More Expensive Now, But Much More Derisked
- Top 10 Russell 2000 weekly gainers and losers as Wall Street crashes
- Edgewise Therapeutics downgraded at Scotiabank on heart disease trial results
- Seeking Alpha’s Quant Rating on Edgewise Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
